国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (2): 109-112.doi: 10.3760/cma.j.issn.1673-422X.2019.02.011

• 综述 • 上一篇    下一篇

非小细胞肺癌新辅助化疗的现状分析

 李琴, 付振明   

  1. 武汉大学人民医院肿瘤科430060
  • 出版日期:2019-02-08 发布日期:2019-04-03
  • 通讯作者: 付振明,Email: davidfuzming@163.com E-mail:davidfuzming@163.com
  • 基金资助:

    国家自然科学基金(81472971、81773555)

Analysis of current status of neoadjuvant chemotherapy for non-small cell lung cancer

Li Qin, Fu Zhenming   

  1. Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China
  • Online:2019-02-08 Published:2019-04-03
  • Contact: Fu Zhenming, Email: davidfuzming@163.com E-mail:davidfuzming@163.com
  • Supported by:

    National Natural Science Foundation of China (81472971, 81773555)

摘要: 肺癌是目前世界上对人类健康威胁最大的恶性肿瘤。目前对于早期及局部进展期可手术切除的非小细胞肺癌患者,国内外指南均推荐采用手术、化疗、放疗多种模式综合治疗。最新研究表明,新辅助化疗可显著改善可切除非小细胞肺癌患者的预后,且有更好的治疗依从性及耐受性。

关键词: 癌, 非小细胞肺, 化学疗法, 辅助

Abstract: Lung cancer has been the most dangerous malignant tumor in the worldwide. Nowadays, for patients with resectable early or local advanced nonsmall cell lung cancer (NSCLC), both domestic and foreign guidelines recommended multidisciplinary treatments like surgery, chemotherapy and radiotherapy. Recent studies have shown that neoadjuvant chemotherapy can significantly improve the prognosis of patients with resectable NSCLC and has better treatment compliance and tolerance.

Key words: Carcinoma, non-small-cell lung, Chemotherapy, adjuvant